Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock - Trevi Therap

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten p…

Trevi raises $150M; Spain and Boston set up biotech fund

Plus, news about UK clinical studies and Kura Oncology: Trevi Therapeutics to sell $150M in shares: The biotech plans to float more than 11.5 million shares at $13 apiece. Trevi is ...

Trevi sells 11.6M shares at $13, aiming to raise about $150M

Underwriters can buy 1.74M more shares within 30 days, and the deal is set to close around April 20, pending customary conditions.